Trial
NCT02871323
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
Celgene; The Leukemia and Lymphoma Society; National Cancer Institute (NCI)
Condition
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
Intervention
Durvalumab
Why stopped
PI decided to withdraw the study after it opened for enrollment but before any patients were enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-08-20